Myomo, Inc. Announces Publication of Significant Clinical Research

Peer-reviewed Results Indicate Significant Reduction in Upper Extremity Impairment with MyoPro®, with Changes Exceeding Clinically Important Thresholds

CAMBRIDGE, Mass., June 27, 2017 – Myomo, Inc. (NYSE MKT: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced publication of an investigator-led clinical study in the Archives of Physical Medicine and Rehabilitation. The study, conducted at the Ohio State University School of Medicine, concluded that upper extremity (UE) impairment is significantly reduced with use of the MyoPro, and these changes exceeded the clinically important difference threshold of standard impairment tests. Read more.